Can-Fite Biopharma Ltd ADR (CANF)

$0.46 -0.02 (-4.43%)
Market Cap 1.71M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 259,200
Avg Vol 210,560
Day's Range N/A - N/A
Shares Out 3.54M
Stochastic %K 1%
Beta 1.01
Analysts Strong Sell
Price Target $7.75

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
whatascam
whatascam Oct. 25 at 5:41 PM
$CANF Somebody tell him
0 · Reply
whatascam
whatascam Oct. 23 at 5:03 PM
$CANF Will close short @ around .07c
1 · Reply
whatascam
whatascam Oct. 22 at 10:57 PM
$CANF Pure scamstonk play #winning
0 · Reply
whatascam
whatascam Oct. 21 at 7:16 PM
$CANF A true delight
0 · Reply
TeresaGrimes250
TeresaGrimes250 Oct. 20 at 4:17 PM
$CANF improving treatment; AITX improving trust — profitable Q2 and debt reduction prove clear management control.
0 · Reply
IndiraSolano436
IndiraSolano436 Oct. 20 at 4:16 PM
$CANF improving treatment; AITX improving trust — profitable Q2 and debt reduction prove clear management control.
0 · Reply
whatascam
whatascam Oct. 20 at 12:04 PM
$CANF Sounds great! Shorts on for multiple rounds of dilution and reverse splits.
0 · Reply
whatascam
whatascam Oct. 17 at 6:55 PM
$CANF That’s how desperate they are for cash. Dropping whatever they can on a Friday. Yet another bio pharm scamstonk. Steer clear.
0 · Reply
deesht
deesht Oct. 17 at 2:59 PM
$CANF Thieves - only one title fits here. Newbies please select some relatable company to trade/invest/ swing trade but don't throw away your money/valuable time ...Go away from this ditch..A well wisher
0 · Reply
Bee202
Bee202 Oct. 17 at 10:31 AM
$CANF WOW
1 · Reply
Latest News on CANF
Can-Fite Reports H1 2025 Financial Results and Clinical Update

Aug 28, 2025, 8:47 AM EDT - 2 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 30, 2025, 7:04 AM EDT - 3 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 12:24 PM EDT - 3 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 17, 2025, 8:55 AM EDT - 6 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 2:28 PM EDT - 6 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 20, 2025, 9:45 AM EDT - 7 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 19, 2025, 9:00 AM EDT - 7 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mar 3, 2025, 6:00 AM EST - 8 months ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 10, 2025, 7:10 AM EST - 9 months ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Feb 5, 2025, 7:00 AM EST - 9 months ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Dec 30, 2024, 7:00 AM EST - 10 months ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Feb 28, 2024, 7:00 AM EST - 1 year ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 30, 2024, 7:00 AM EST - 1 year ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Jan 29, 2024, 7:00 AM EST - 1 year ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 20, 2023, 7:00 AM EST - 2 years ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Dec 4, 2023, 7:00 AM EST - 2 years ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Nov 30, 2023, 7:00 AM EST - 2 years ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Nov 21, 2023, 1:53 PM EST - 2 years ago

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Nov 21, 2023, 7:00 AM EST - 2 years ago

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

whatascam
whatascam Oct. 25 at 5:41 PM
$CANF Somebody tell him
0 · Reply
whatascam
whatascam Oct. 23 at 5:03 PM
$CANF Will close short @ around .07c
1 · Reply
whatascam
whatascam Oct. 22 at 10:57 PM
$CANF Pure scamstonk play #winning
0 · Reply
whatascam
whatascam Oct. 21 at 7:16 PM
$CANF A true delight
0 · Reply
TeresaGrimes250
TeresaGrimes250 Oct. 20 at 4:17 PM
$CANF improving treatment; AITX improving trust — profitable Q2 and debt reduction prove clear management control.
0 · Reply
IndiraSolano436
IndiraSolano436 Oct. 20 at 4:16 PM
$CANF improving treatment; AITX improving trust — profitable Q2 and debt reduction prove clear management control.
0 · Reply
whatascam
whatascam Oct. 20 at 12:04 PM
$CANF Sounds great! Shorts on for multiple rounds of dilution and reverse splits.
0 · Reply
whatascam
whatascam Oct. 17 at 6:55 PM
$CANF That’s how desperate they are for cash. Dropping whatever they can on a Friday. Yet another bio pharm scamstonk. Steer clear.
0 · Reply
deesht
deesht Oct. 17 at 2:59 PM
$CANF Thieves - only one title fits here. Newbies please select some relatable company to trade/invest/ swing trade but don't throw away your money/valuable time ...Go away from this ditch..A well wisher
0 · Reply
Bee202
Bee202 Oct. 17 at 10:31 AM
$CANF WOW
1 · Reply
whatascam
whatascam Oct. 14 at 2:40 PM
$CANF Perfect 👌
0 · Reply
whatascam
whatascam Oct. 13 at 12:49 PM
$CANF Ooof
0 · Reply
whatascam
whatascam Oct. 10 at 10:24 AM
$CANF
0 · Reply
mmerryweather
mmerryweather Oct. 9 at 7:56 PM
$CANF Again - Do NOT fall for management news that will be another attempt to con buyers into buying the stock. They have run this con for over 10 years. Let them die. They are whores. I have never owned the stock but will be a major buyer at $.29 to $.31 per share.
0 · Reply
mmerryweather
mmerryweather Oct. 9 at 7:36 PM
$CANF New ALL TIME LOW HISTORY OF COMPANY (30 years) at $.56 per share. Again - stay away until $.30 per share. May be lower ($.24 to $.27 per share) for "tax loss selling season" in December. Stay away and be looking for some kind of con job "news" the company will release in hopes the stock will rise. Terrible whores that run the company. Let them die.
0 · Reply
whatascam
whatascam Oct. 8 at 10:02 PM
$CANF If you like dilution and reverse splits this stock is for you. You sad bagholding Robinhooder!
0 · Reply
mmerryweather
mmerryweather Oct. 8 at 6:47 PM
$CANF For "whatascam:" - Given what you have posted in the past, the best thing for you to do is get out and stay out of the market. Take your $100.00 account and pay the rent with it. To suggest "shorting" with the stock at all time lows shows just how uninformed you are with respect the the markets. Save yourself and exit the market forever.
0 · Reply
whatascam
whatascam Oct. 8 at 5:52 PM
$CANF Time to short for quick gains.
0 · Reply
mmerryweather
mmerryweather Oct. 8 at 5:38 PM
$CANF It is underway! Now $.57 per share with more downside coming in the next days. To fund salaries, management must sell stock. They will not be able to raise additional funds and will attempt to steal as much as they can before that issue hits home. Do not listen to any attempt to run the con with phony "good news." These people are nothing more than con artists. The company will have value at $.30 per share and not before.
0 · Reply
mmerryweather
mmerryweather Oct. 8 at 3:42 PM
$CANF New all time history of the company low share price just printed at 59 cents per share. Single buyer of 8.3 million shares at $.60 on 7-28-2025 is now in a LOSS POSITION. If the buyer decides to go - don't be in the way with any ownership of stock. Beware of any potential attempt to print GOOD NEWS to get the stock price up. Management will do anything possible to keep the paycheck incoming. Just wait for the price to be cut in half from here and print at $.30 per share. Don't buy a single share at these prices.
0 · Reply
mmerryweather
mmerryweather Oct. 8 at 2:06 PM
$CANF I posted on 9-22-25 & 9-23-25 what would happen with respect to a reverse stock split. It did in fact occur but It is far worse than I thought and the company attempted to hide the news. When the idiots in the market place finally read the news, you had better be out of the way. New target upon approval of the reverse split: $.31 to $.34 per share. It is pure death but I will be a massive buyer at $.29 to $.31.
0 · Reply
peepthestamp
peepthestamp Oct. 6 at 1:35 PM
$CANF $JXG $MASK $SNGX $SOPA -Aging Well 👀
0 · Reply